Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Low leverage ⢠Earnings reversal TBPH offers exceptional liquidity and low debt, but recent losses, negative cash flow, and volatile profitability warrant caution despite relatively moderate valuation.
Price Behavior
Key Price Behavior Insights: ⢠Tight price range ⢠$17.08 resistance ⢠$17.00 support Support Level: $17.00â$17.01; secondary $16.92â$16.95 Resistance Level: $17.08 TBPH was range-bound with a slight upward bias last month; hold above $17.00 for constructive momentum, while a break above $17.08 is needed for upside continuation.
Sentiment & News
Key News Insights: ⢠$17 Offer ⢠Fairness Probe ⢠Institutional Buying Theravance Biopharma trades near Zymeworks' $17-per-share offer amid fairness scrutiny and continued institutional buying.
AI Summary
TBPH is a merger-arbitrage trade, not a standalone biotech growth story: at ~$17.06, upside is largely limited to an uncertain, non-tradable ampreloxetine CVR, while a delayed or failed Zymeworks deal could expose weaker standalone cash flow and concentrated YUPELRI dependence. Investors should prioritize closing and litigation/timing risk over operating-growth catalysts.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |